MedDataX Logo

Effects of LP28 on Immunity Enhancement in the Elderly

NCT ID: NCT06724185

Last Updated: 2024-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-09

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Due to the increasing attention on aging-related health issues, this study focuses on the elderly population as participants. The aim is to investigate whether supplementation with Lactobacillus plantarum LP28 can effectively enhance immunity, reduce the frequency and severity of common cold infections, and ultimately promote overall health in the elderly.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Common Cold Immunity Probiotic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LP28 capsule

Subjects will take two capsule of the experimental group(LP28 capsule) within 30 minutes before breakfast and dinner each day.

Group Type EXPERIMENTAL

LP28 capsule

Intervention Type DIETARY_SUPPLEMENT

LP28 capsule : 5.0×10\^9 CFU/capsule

Placebo capsule

Subjects will take two placebo capsule within 30 minutes before breakfast and dinner each day.

Group Type PLACEBO_COMPARATOR

Placebo Capsule

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LP28 capsule

LP28 capsule : 5.0×10\^9 CFU/capsule

Intervention Type DIETARY_SUPPLEMENT

Placebo Capsule

Maltodextrin

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Those who had symptoms of common cold or tonsillitis at least twice in the past year.

Exclusion Criteria

* People who have liver, kidney, immune, or neoplastic diseases diagnosed by doctor.
* People with mental illnesses such as schizophrenia or depression.
* People who have allergic rhinitis.
* People who have a current condition of drug or alcohol dependence.
* Any person is deemed inappropriate by the researcher for the clinical trial.
Minimum Eligible Age

50 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Synbio Tech Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Chung Hsing University

Taichung, , Taiwan

Site Status RECRUITING

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Han-Yin Hsu

Role: CONTACT

Phone: +886-07-6955680 Ext. 553

Email: [email protected]

Chia-Chia Lee, PhD

Role: CONTACT

Phone: +886-07-6955680 Ext. 550

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ching-Lin Wu, Professor

Role: primary

Jeng-Jer Shieh, Professor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SF24108C

Identifier Type: -

Identifier Source: org_study_id